Animal models of systemic sclerosis: prospects and limitations.
about
The immune pathogenesis of scleroderma: context is everythingTherapeutic targeting of redox signaling in myofibroblast differentiation and age-related fibrotic diseaseTime-dependent and somatically acquired mitochondrial DNA mutagenesis and respiratory chain dysfunction in a scleroderma model of lung fibrosisMolecular targets for therapy in systemic sclerosisTargeting the myofibroblast genetic switch: inhibitors of myocardin-related transcription factor/serum response factor-regulated gene transcription prevent fibrosis in a murine model of skin injury.Tie2 as a novel key factor of microangiopathy in systemic sclerosis.Surgical approaches to create murine models of human wound healingTargeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis.Combined effect of genetic background and gender in a mouse model of bleomycin-induced skin fibrosis.Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis.Gadolinium-induced fibrosis is counter-regulated by CCN3 in human dermal fibroblasts: a model for potential treatment of nephrogenic systemic fibrosis.PDGF-BB Promotes Type I IFN-Dependent Vascular Alterations and Monocyte Recruitment in a Model of Dermal Fibrosis.The cannabinoid quinol VCE-004.8 alleviates bleomycin-induced scleroderma and exerts potent antifibrotic effects through peroxisome proliferator-activated receptor-γ and CB2 pathwaysAngiotensin II induces skin fibrosis: a novel mouse model of dermal fibrosisProtective role for miR-9-5p in the fibrogenic transformation of human dermal fibroblasts.OX40L blockade protects against inflammation-driven fibrosis.Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis.β-catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis.Targeted therapies for systemic sclerosis.Animal models of scleroderma: current state and recent development.Double heterozygous mice for Klf5 and Fli1 genes: a new animal model of systemic sclerosis recapitulating its three cardinal pathological features.Systemic sclerosis and localized scleroderma--current concepts and novel targets for therapy.Diagnosis and Management of Systemic Sclerosis: A Practical Approach.Recent advances in animal models of systemic sclerosis.Myeloid Populations in Systemic Autoimmune Diseases.A modified graft-versus-host-induced model for systemic sclerosis, with pulmonary fibrosis in Rag2-deficient mice.Histone Demethylation and Toll-like Receptor 8-Dependent Cross-Talk in Monocytes Promotes Transdifferentiation of Fibroblasts in Systemic Sclerosis Via Fra-2.Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis.Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies.Glycyrrhizin Ameliorates Fibrosis, Vasculopathy, and Inflammation in Animal Models of Systemic Sclerosis.Searching for a good model for systemic sclerosis: the molecular profile and vascular changes occurring in UCD-200 chickens strongly resemble the early phase of human systemic sclerosis.Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis.Activation of liver X receptors inhibits experimental fibrosis by interfering with interleukin-6 release from macrophages.Heat shock protein 90 (Hsp90) inhibition targets canonical TGF-β signalling to prevent fibrosis.Inactivation of evenness interrupted (EVI) reduces experimental fibrosis by combined inhibition of canonical and non-canonical Wnt signalling.Female Reproductive System and Immunology.Topoisomerase I peptide-loaded dendritic cells induce autoantibody response as well as skin and lung fibrosis.The nuclear receptor constitutive androstane receptor/NR1I3 enhances the profibrotic effects of transforming growth factor β and contributes to the development of experimental dermal fibrosis.Editorial: Bench to Bedside-and Back Again: Finding the Goldilocks Zone Within the Scleroderma Universe.Induction of Scleroderma Fibrosis in Skin-Humanized Mice by Administration of Anti-Platelet-Derived Growth Factor Receptor Agonistic Autoantibodies.
P2860
Q24633658-26F146C2-6DAB-4B54-8A0B-460A7B8743B6Q26827629-28A63D1C-382F-460D-9B3A-2BA4529848BEQ28388130-B2FDEA64-0BFD-4E44-B8D2-FFE77CCCC6D1Q28484123-672BEA10-5872-4737-B7AA-890DEFE32EBBQ33603627-F8C45130-3BB4-43F0-8C12-ADA2E9E4438CQ33730294-35862877-411A-4DAB-896D-E2AFC86CC5E1Q34373111-422286D9-CAD5-40A8-AB75-1E62B26C0BE3Q34452035-0E881B3D-BE38-4D13-B90B-D740F70BC916Q35710188-F1899BF3-2175-4962-B845-5E1A11B775B4Q35863725-3A676743-15C9-4FB3-AC2F-13DC6959F854Q36010507-0AED32BA-3344-4316-A0EB-515EA487A959Q36130126-9F1EBB4E-49A9-49F7-9BC0-23BB75B4FAFDQ36591533-2CC12C7E-290F-4085-BBC0-7C3AEF61B587Q36633452-CF56F9AA-943A-43E0-BD58-B668C1AAA327Q36965488-8C44D9BF-BE16-4506-A303-6FAD93474FBFQ37086713-D6052AE2-53B8-49D2-B87A-EA85C2D10173Q37471585-C8173D3E-096E-415C-8EA5-9F687F14FFF2Q37634132-4CD4FA88-A55D-4F63-B895-903D18154781Q38097276-D02E4E5D-E01D-464B-B3A7-74FBC32FF679Q38154834-282FBF1B-8A34-4545-9D37-47D4A2DBBCFFQ38489606-C54241EB-E3BB-403C-A1BB-B754D9AA753BQ38636049-E4A73C32-07E8-4677-8887-06384364C1A0Q38667111-01A5B95F-16F9-459B-87E6-DE406F5C53C2Q38701983-0AB8C53D-02D6-40B5-96C3-5630FC106C1EQ38772739-27BB15A1-29F4-4A71-81D5-09BFCCB8B7BDQ40047502-F8650226-F588-4612-872B-2D74919A8982Q40057489-7D5EC042-255A-4FD8-843E-85C6FB4A99CEQ41095169-0072A203-006E-4281-AEEF-B6676654ED6CQ41147581-E4E9821A-498E-40EB-8EEA-E2CA98E017B7Q41980258-603039DE-1BB7-4158-84D0-E4B36B30ED0EQ42416370-17AE2BC8-75C5-4D8F-B580-715E4F166063Q42638573-D3EACC25-E3E9-4C3A-B7AA-B5610285C332Q45207632-A56F9359-3D8C-47D1-B8AD-41C9949EEBA3Q45971063-6348F628-2951-42AC-BBE7-C0DA07CC97AFQ46121852-B7D432B7-924C-48F5-8B4D-DEEAE27EDDA1Q47619318-9C3B0A49-402A-4A3D-A27F-29ADDE066C98Q48945028-89C3120C-1EC6-4D60-BC33-05FF02AD5197Q50050279-2587E311-7F6F-41CD-A836-97EC187407FBQ50091398-9249AC32-9A10-4BF6-9344-AA522587CC1DQ50243147-3B631757-72AF-4CAF-B834-E6EDA801B4DA
P2860
Animal models of systemic sclerosis: prospects and limitations.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Animal models of systemic sclerosis: prospects and limitations.
@en
Animal models of systemic sclerosis: prospects and limitations.
@nl
type
label
Animal models of systemic sclerosis: prospects and limitations.
@en
Animal models of systemic sclerosis: prospects and limitations.
@nl
prefLabel
Animal models of systemic sclerosis: prospects and limitations.
@en
Animal models of systemic sclerosis: prospects and limitations.
@nl
P2093
P2860
P356
P1476
Animal models of systemic sclerosis: prospects and limitations.
@en
P2093
Christian Beyer
Jörg H W Distler
Oliver Distler
P2860
P304
P356
10.1002/ART.27647
P50
P577
2010-10-01T00:00:00Z